



Supporting Information

for

Cholyl 1,3,4-oxadiazole hybrid compounds: design, synthesis and antimicrobial assessment

Anas J. Rasras, Mohamed El-Naggar, Nesreen A. Safwat and Raed A. Al-Qawasmeh

Beilstein J. Org. Chem. **2022**, *18*, 631–638. doi:10.3762/bjoc.18.63

Experimental procedures, characterization of products, and copies of NMR spectra

Table of contents

1. Experimental section	S2
1.1 General information	S2
1.2 Procedure for preparation of 1,3,4-oxadiazole-2-thiol (2)	S2
1.3 Procedure for preparation of 2-(propargylthio)-1,3,4-oxadiazole (3)	S3
1.4 General procedure for preparation of compounds 4a–v	S3
2. Antimicrobial activity assay	S14
3. Copies of NMR spectra	S16
4. References	S65

1. Experimental section

1.1. General information

NMR spectra were measured with tetramethylsilane (TMS) as the internal standard. NMR spectra were recorded on a Bruker Avance III-500 MHz spectrometer type (^1H NMR, 500 MHz; ^{13}C NMR, 125 MHz). Chemical shifts (δ) are reported in ppm. High resolution mass spectra (HRMS) were recorded in either positive or negative ion mode by electrospray ionization using a Bruker Daltonics Apex IV, 7.0 T Ultra Shield Plus (Bremen, Germany). Melting points (mp) were determined on an electrothermal melting point apparatus and are uncorrected. Unless otherwise noted, all chemicals and solvents used were obtained from Fluka and Aldrich and used without further purification. THF was distilled over sodium metal and benzophenone. Reactions were monitored by thin layer chromatography (TLC) using Merck aluminum plates precoated with silica gel PF254 (20 × 20 × 0.2 mm) and detected by visualization of the plate under a UV lamp (λ = 254 nm).

1.2. Procedure for preparation of (3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-mercapto-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (**2**)

To a solution of cholyhydrazide **1** (4.10 g, 9.70 mmol, 1.0 equiv) in 50 mL EtOH was added carbon disulfide (1.76 mL, 29.10 mmol, 3.0 equiv) and Et₃N (1.62 mL, 11.64 mmol, 1.2 equiv). The solution was refluxed for 24 h, then cooled to room temperature and acidified with HCl (0.1 M in H₂O) and let stand for 3 h at room temperature. The formed precipitate was filtered and washed with H₂O (3 × 10 mL) and petroleum ether (2 × 10 mL) to give oxadiazole-2-thiol **2** (4.19 g, 8.80 mmol, 93%) as a yellow solid. mp 237-239 °C. ^1H NMR (500 MHz, DMSO-*d*₆): δ 0.59 (s, 3H, CH₃); 0.80 (s, 3H, CH₃); 0.97 (d, 3H, *J* = 5.2, CH₃); 1.09–2.08 (m, 20H, CH₂ and CH); 2.08–2.33 (m, 2H, CH₂); 2.58–2.64 (m, 1H, CH); 2.66–2.82 (m, 1H, CH); 3.11–3.26 (m, 1H, CH); 3.61 (m, 1H, CH); 3.78 (m, 1H, CH); 3.87–4.37 (br, 3H, OH); 14.27 (s, 1H, SH). ^{13}C NMR (125 MHz, DMSO-*d*₆): δ 12.3, 16.8, 22.0, 22.6, 22.8, 26.2, 27.2, 28.5, 30.4, 31.3, 34.4, 34.9, 35.3, 39.6, 39.8, 39.9, 41.4, 41.5, 45.8, 45.9, 66.2, 70.4, 70.9, 164.7, 177.7. HRMS (ESI-MS): *m/z* calcd for C₂₅H₃₉N₂O₄S: 463.2636 [M-H][−]; found 463.2637.

1.3. Procedure for preparation of (3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-10,13-dimethyl-17-((*R*)-4-(5-(prop-2-yn-1-ylthio)-1,3,4-oxadiazol-2-yl)butan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (3**):**

To a solution of oxadiazole-2-thiol **2** (6.94 g, 14.93 mmol, 1.0 equiv) in acetonitrile (50 mL) was added Na₂CO₃ (4.75 g, 44.80 mmol, 3 equiv) and the mixture was stirred for 20 min at room temperature followed by heating to 50 °C. Then, 3-bromopropyne solution (80% in toluene, 2.40 mL, 22.40 mmol, 1.5 equiv) was added and the mixture was stirred for 24 h at 50 °C. Na₂CO₃ was removed by filtration and the solvent was evaporated. To the residue 20 mL of water were added and extracted with EtOAc (2 × 20 mL). The organic layer was washed with water (2 × 20 mL), dried over MgSO₄, and evaporated in vacuum yielding compound **3** (6.15 g, 12.23 mmol, 82%) as a pale brown solid. mp 155-157 °C. ¹H NMR (500 MHz, CDCl₃): δ 0.67 (s, 3H, CH₃); 0.88 (s, 3H, CH₃); 1.04 (d, 3H, J= 6.4, CH₃); 1.32–2.04 (m, 20H, CH₂ and CH); 2.11-2.27 (m, 2H, CH); 2.31 (t, 1H, J= 2.5, alkyne); 2.71-2.80 (m, 1H, CH); 2.84-2.94 (m, 1H, CH); 3.38-3.52 (m, 1H, CH); 3.85 (m, 1H, CH); 3.97 (m, 3H, CH₂ and CH). ¹³C NMR (125 MHz, CDCl₃): δ 12.5, 17.3, 21.0, 22.4, 22.4, 23.2, 26.4, 27.5, 28.2, 29.7, 30.2, 32.4, 34.5, 34.7, 35.2, 39.4, 39.4, 41.4, 41.7, 46.5, 46.7, 68.5, 72.1, 72.9, 73.0, 77.4, 162.3, 169.1. HRMS (ESI-MS): m/z calcd for C₂₈H₄₂N₂NaO₄S: 525.2758 [M+Na]⁺; found 525.2756.

1.4. General procedure for preparation of compounds 4a–v:

Alkyne **3** (0.30 g, 0.597 mmol, 1 equiv), the corresponding amine (0.716 mmol, 1.2 equiv), aqueous formaldehyde (35%, 1 mL), and CuI (20 mg) in 2 mL DMSO were stirred at room temperature for 3 h. Then, 10 mL of water were added, the mixture extracted with EtOAc (2 × 20 mL), dried and evaporated. The residue was purified by column chromatography (EtOAc/MeOH 10:1).

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-10,13-Dimethyl-17-((*R*)-4-(5-((4-(4-phenylpiperazin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4a)

Colorless oil (0.313 g, 77% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.63 (s, 3H, CH₃); 0.84 (s, 3H, CH₃); 0.99 (d, 3H, J = 6.0, CH₃); 1.30–1.95 (m, 20H, CH₂ and CH); 2.09–2.29 (m, 2H, CH); 2.71 (m, 4H, CH₂); 2.84 (m, 2H, CH₂); 3.21 (m, 4H, CH₂); 3.38 (m, 3H, CH₂ and CH); 3.80 (m, 1H, CH); 3.91 (m, 1H, CH); 3.99 (s, 2H, CH₂); 6.78–6.85 (m, 1H, CH-aromatic); 6.89–6.98 (m, 2H, CH-aromatic); 7.18–7.24 (m, 2H, CH-aromatic). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.5, 22.3, 22.4, 23.2, 26.4, 27.5, 28.2, 30.4, 32.3, 34.6, 34.7, 35.2, 35.3, 39.4, 39.6, 41.4, 41.7, 46.4, 46.6, 47.1, 48.8, 51.8, 68.4, 71.8, 72.9, 116.2, 120.0, 129.1, 151.0, 162.3, 169.0. HRMS (ESI-MS): m/z calcd for C₃₉H₅₇N₄O₄S: 677.4095 [M+H]⁺; found 677.4096.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(4-Fluorophenyl)piperazin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4b)

Yellow oil (0.342 g, 83% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.65 (s, 3H, CH₃); 0.87 (s, 3H, CH₃); 1.01 (d, 3H, J = 5.8, CH₃); 1.31–1.97 (m, 20H, CH₂ and CH); 2.10–2.29 (m, 2H, CH); 2.57–2.66 (m, 1H, CH); 2.67–2.82 (m, 4H, CH₂ and CH); 2.82–2.92 (m, 1H, CH); 3.08–3.25 (m, 4H, CH₂); 3.36–3.53 (m, 3H, CH₂ and CH); 3.83 (m, 1H, CH); 3.94 (m, 1H, CH); 4.02 (s, 2H, CH₂); 4.13–4.39 (br, 3H, OH); 6.82–6.88 (m, 2H, CH-aromatic); 6.93–7.04 (m, 2H, CH-aromatic). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.5, 22.3, 22.4, 23.2, 26.4, 27.5, 28.2, 30.4, 32.3, 34.6, 34.7, 35.2, 35.3, 39.4, 539.5, 41.4, 41.6, 46.4, 46.6, 47.1, 49.7, 51.6, 68.4, 71.8, 73.0, 115.5 (d, J C–F = 22.2 Hz), 118.1 (d, J C–F = 7.7 Hz), 147.6, 156.3, 164.3, 170.2. HRMS (ESI-MS): m/z calcd for C₃₉H₅₆FN₄O₄S: 695.4001 [M+H]⁺; found 695.3976.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(4-(2-Fluorophenyl)piperazin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethyl hexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4c)

Colorless oil (0.373 g, 90% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.66 (s, 3H, CH₃); 0.87 (s, 3H, CH₃); 1.02 (d, 3H, J = 6.2, CH₃); 1.19–1.98 (m, 20H, CH₂ and CH); 2.15–2.24 (m, 2H, CH); 2.64–3.01 (m, 6H, CH₂ and CH); 3.09–3.28 (m, 4H, CH₂); 3.37–3.54 (m, 3H, CH₂ and CH); 3.83 (m, 1H, CH); 3.95 (m, 1H, CH); 4.04 (s, 2H, CH₂); 4.25–4.48 (br, 3H, OH); 6.90–7.16 (m, 4H, CH-aromatic). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.5, 22.3, 22.4, 23.2, 26.3, 27.5, 28.1, 30.3, 32.3, 34.6, 34.7, 35.2, 35.3, 39.4, 39.5, 41.4, 41.6, 46.4, 46.6, 47.1, 49.8, 51.6, 68.4, 71.9, 73.0, 116.1 (d, J C–F = 20.6 Hz), 119.0 (d, J C–F = 2.6 Hz), 122.7 (d, J C–F = 7.9 Hz); 124.5 (d, J C–F = 3.5 Hz); 139.6 (d, J C–F = 8.2 Hz); 155.6 (d, J C–F = 245.9 Hz), 162.4, 169.4. HRMS (ESI-MS): m/z calcd for C₃₉H₅₆FN₄O₄S: 695.4001 [M+H]⁺; found 695.4020.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(4-(4-Methoxyphenyl)piperazin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethyl hexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4d)

Yellow oil (0.407 g, 96% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.65 (s, 3H, CH₃); 0.86 (s, 3H, CH₃); 1.00 (d, 3H, J = 5.6, CH₃); 1.31–1.99 (m, 20H, CH₂ and CH); 2.16–2.23 (m, 2H, CH); 2.68–2.96 (m, 6H, CH₂ and CH); 3.04–3.24 (m, 4H, CH₂); 3.36–3.53 (m, 3H, CH₂ and CH); 3.75 (s, 3H, OCH₃); 3.83 (m, 1H, CH); 3.94 (m, 1H, CH); 4.04 (s, 2H, CH₂); 4.40–4.59 (bs, 3H, OH); 6.79–6.86 (m, 2H, CH-aromatic); 6.86–6.94 (m, 2H, CH-aromatic). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.5, 22.3, 22.4, 23.2, 26.3, 27.5, 28.1, 30.2, 32.3, 34.5, 34.7, 35.2, 35.2, 39.4, 39.4, 41.4, 41.6, 46.4, 46.6, 50.1, 50.1, 51.5, 55.5, 68.4, 71.8, 73.0, 114.4, 118.5, 154.1, 163.2, 172.6. HRMS (ESI-MS): m/z calcd for C₄₀H₅₉N₄O₅S: 707.4201 [M+H]⁺; found 707.4180.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-10,13-Dimethyl-17-((*R*)-4-(5-((4-(4-(pyridin-2-yl)piperazin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4e)

Brown oil (0.296 g, 73% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.65 (s, 3H, CH₃); 0.87 (s, 3H, CH₃); 1.01 (d, 3H, J = 6.2, CH₃); 1.32–2.05 (m, 20H, CH₂ and CH); 2.10–2.28 (m, 2H, CH); 2.65–2.70 (m, 4H, CH₂ and CH); 2.83–2.94 (m, 2H, CH₂); 3.31–3.42 (m, 3H, CH₂ and CH); 3.51–3.64 (m, 4H, CH₂); 3.82 (m, 1H, CH); 3.94 (m, 1H, CH); 4.00 (s, 2H, CH₂); 6.55–6.76 (dd, 2H, J = 17.0, 7.4, CH-aromatic); 7.48 (t, 1H, J = 7.4, CH-aromatic); 8.17 (d, 1H, J = 3.2, CH-aromatic). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.5, 22.3, 22.4, 23.2, 26.4, 27.5, 28.2, 30.4, 32.4, 34.6, 34.7, 35.2, 35.3, 39.4, 39.6, 41.4, 41.7, 45.0, 46.4, 46.6, 47.2, 51.7, 68.4, 71.8, 72.9, 107.3, 113.5, 137.7, 147.7, 159.2, 162.5, 169.0. HRMS (ESI-MS): m/z calcd for C₃₈H₅₆N₅O₄S: 678.4048 [M+H]⁺; found 678.4037.

1-(4-(4-(4-((5-((*R*)-3-((3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl)butyl)-1,3,4-oxadiazol-2-yl)thio)but-2-yn-1-yl)piperazin-1-yl)phenyl)ethan-1-one (4f)

Yellow oil (0.411 g, 96% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.64 (s, 3H, CH₃); 0.85 (m, 3H, CH₃); 1.00 (d, 3H, J = 5.9, CH₃); 1.31–1.90 (m, 20H, CH₂ and CH); 2.10–2.24 (m, 2H, CH₂); 2.50 (s, 3H, CH₃); 2.69–2.85 (m, 6H, CH₂ and CH); 3.31–3.42 (m, 7H, CH₂ and CH); 3.81 (m, 1H, CH); 3.92 (m, 1H, CH); 3.99 (s, 2H, CH₂); 6.86 (d, 2H, J = 8.3, CH-aromatic); 7.86 (d, 2H, J = 8.3, CH-aromatic). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.4, 22.2, 22.4, 23.1, 26.1, 26.3, 27.5, 28.1, 30.3, 32.3, 34.6, 34.7, 35.2, 35.2, 39.4, 39.5, 40.8, 41.4, 41.6, 46.4, 46.5, 46.9, 51.2, 68.3, 71.8, 72.9, 113.6, 127.8, 130.4, 153.9, 163.3, 169.2, 196.7. HRMS (ESI-MS): m/z calcd for C₄₁H₅₉N₄O₄S: 719.4201 [M+H]⁺; found 719.4241.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(4-(2-Hydroxyethyl)piperazin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4g)

Yellow oil (0.307 g, 79% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.66 (s, 3H, CH₃); 0.87 (s, 3H, CH₃); 1.03 (d, 3H, J = 6.4, CH₃); 1.32–1.97 (m, 20H, CH₂ and CH); 2.11–2.27 (m,

2H, CH₂); 2.44-2.73 (m, 10H, CH₂ and CH); 2.73–2.79 (m, 1H, CH); 2.85–2.93 (m, 1H, CH); 3.28 (m, 2H, CH₂); 3.36-3.45 (m, 1H, CH); 3.64-3.72 (m, 2H, CH); 3.82 (m, 1H, CH); 3.94 (m, 1H, CH); 3.97 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.6, 22.2, 22.4, 23.2, 26.4, 27.6, 28.2, 30.3, 32.4, 34.6, 34.7, 35.3, 39.4, 39.6, 41.5, 41.7, 46.4, 46.5, 46.9, 51.3, 52.7, 57.7, 58.3, 59.3, 68.3, 71.8, 72.9, 79.0, 79.6, 162.4, 169.2. HRMS (ESI-MS): m/z calcd for C₃₅H₅₇N₄O₅S: 645.4044 [M+H]⁺; found 645.4053.

4-(4-((5-((*R*)-3-((3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl)butyl)-1,3,4-oxadiazol-2-yl)thio)but-2-yn-1-yl)piperazine-1-carbaldehyde (4h)

Yellow oil (0.352 g, 94% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.66 (s, 3H, CH₃); 0.86 (m, 3H, CH₃); 1.03 (d, 3H, J= 5.8, CH₃); 1.31–1.96 (m, 20H, CH₂ and CH); 2.07-2.26 (m, 2H, CH₂); 2.38-2.60 (m, 4H, CH₂ and CH); 2.68-2.78 (m, 1H, CH); 2.85-2.90 (m, 1H, CH); 3.29-3.47 (m, 5H, CH₂ and CH); 3.58 (s, 2H, CH₂); 3.82 (m, 1H, CH); 3.94 (m, 1H, CH); 3.98 (s, 2H, CH₂); 8.01 (s, 1H, CHO). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.4, 22.2, 22.4, 23.2, 26.3, 27.5, 28.1, 30.3, 32.4, 34.6, 34.7, 35.3, 35.3, 39.4, 39.5, 41.4, 41.6, 45.2, 46.4, 46.5, 47.1, 51.0, 68.3, 71.8, 72.9, 160.8, 162.4, 169.1. HRMS (ESI-MS): m/z calcd for C₃₄H₅₂N₄NaO₅S: 651.3551 [M+Na]⁺; found 651.3562.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(4-Methylpiperazin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4i)

White solid (0.353 g, 96% yield), m.p: 82-83 °C. ¹H NMR (500 MHz, CDCl₃): δ 0.66 (s, 3H, CH₃); 0.87 (m, 3H, CH₃); 1.03 (d, 3H, J= 6.4, CH₃); 1.33–1.98 (m, 20H, CH₂ and CH); 2.08-2.23 (m, 2H, CH₂); 2.34 (s, 3H, NCH₃); 2.60 (m, 4H, CH₂ and CH); 2.72-2.79 (m, 1H, CH); 2.85-2.92 (m, 1H, CH); 2.93-3.18 (m, 4H, CH₂); 3.33 (s, 2H, CH₂); 3.35-3.47 (m, 1H, CH); 3.82 (m, 1H, CH); 3.95 (m, 1H, CH); 3.99 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.3, 21.5, 22.3, 22.4, 23.2, 26.4, 27.5, 28.2, 30.4, 32.3, 34.7, 34.7, 35.2, 35.3, 39.4, 39.6, 41.5, 41.7, 45.6, 46.4, 46.6, 47.0, 51.4, 54.7, 68.3, 71.8, 72.9, 78.7, 79.8, 162.5, 169.0. HRMS (ESI-MS): m/z calcd for C₃₄H₅₅N₄O₄S: 615.3939 [M+H]⁺; found 615.3957.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(4-Ethylpiperazin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4j)

Yellow oil (0.324 g, 86% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.66 (s, 3H, CH₃); 0.87 (m, 3H, CH₃); 1.03 (d, 3H, J= 6.4, CH₃); 1.10 (t, 3H, J= 7.2, CH₃); 1.32–1.97 (m, 20H, CH₂ and CH); 2.13–2.25 (m, 2H, CH₂); 2.47 (q, 2H, J= 7.2, NCH₂); 2.60 (m, 4H, CH₂ and CH); 2.69–2.78 (m, 1H, CH); 2.82–2.91 (m, 1H, CH); 2.91–3.14 (m, 4H, CH₂); 3.28 (s, 2H, CH₂); 3.36–3.44 (m, 1H, CH); 3.82 (m, 1H, CH); 3.94 (m, 1H, CH); 3.99 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 11.6, 12.4, 17.2, 21.5, 22.3, 22.4, 23.2, 26.3, 27.5, 28.2, 30.4, 32.4, 34.7, 34.7, 35.2, 35.3, 39.4, 39.6, 41.5, 41.6, 46.4, 46.6, 47.0, 51.6, 52.1, 52.3, 68.3, 71.8, 72.9, 78.6, 79.9, 162.6, 169.0. HRMS (ESI-MS): m/z calcd for C₃₅H₅₇N₄O₄S: 629.4095 [M+H]⁺; found 629.4121.

***N*-Isopropyl-2-(4-(4-((5-((*R*)-3-((3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl)butyl)-1,3,4-oxadiazol-2-yl)thio)but-2-yn-1-yl)piperazin-1-yl)acetamide (4k)**

Yellow oil (0.217 g, 52% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.64 (s, 3H, CH₃); 0.84 (s, 3H, CH₃); 1.01 (d, 3H, J= 6.4, CH₃); 1.15 (d, 6H, J= 6.6, CH₃); 1.28–1.90 (m, 20H, CH₂ and CH); 2.07–2.25 (m, 2H, CH₂); 2.46–2.55 (m, 6H, CH₂ and CH); 2.66–2.76 (m, 2H, CH₂); 2.77–2.90 (m, 2H, CH₂); 2.99 (s, 2H, CH₂); 3.28 (s, 2H, CH₂); 3.35–3.41 (m, 1H, CH); 3.74–3.83 (m, 1H, CH); 3.86–3.94 (m, 1H, CH); 3.98 (s, 2H, CH₂); 4.05 (sep, 1H, CH); 7.08 (d, 1H, J= 7.7, NH). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.5, 22.2, 22.3, 22.6, 22.7, 23.1, 26.2, 27.5, 28.1, 30.2, 32.4, 34.6, 34.7, 35.2, 35.3, 39.4, 39.5, 41.4, 41.5, 46.3, 46.6, 46.8, 51.6, 53.0, 61.2, 68.2, 71.7, 72.9, 79.0, 79.3, 162.3, 168.9, 169.1. HRMS (ESI-MS): m/z calcd for C₃₈H₆₂N₅O₅S: 700.4466 [M+H]⁺; found 700.4487.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-10,13-Dimethyl-17-((*R*)-4-(5-((4-thiomorpholinobut-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4l)

Brown oil (0.284 g, 77% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.66 (s, 3H, CH₃); 0.86 (m, 3H, CH₃); 1.02 (d, 3H, J= 6.3, CH₃); 1.31–1.92 (m, 20H, CH₂ and CH); 2.12–2.24 (m,

2H, CH₂); 2.70 (m, 4H, CH₂); 2.75 (m, 4H, CH₂); 3.24-3.31 (m, 3H, CH₂ and CH); 3.37-3.46 (m, 2H, CH₂); 3.75-3.82 (m, 1H, CH); 3.90-3.94 (m, 1H, CH); 4.00 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.5, 22.3, 22.4, 23.2, 26.3, 27.5, 27.9, 28.2, 30.3, 32.3, 34.6, 34.7, 35.2, 35.2, 39.4, 39.6, 41.4, 41.7, 46.4, 46.6, 48.3, 53.7, 68.3, 71.8, 72.9, 79.0, 79.5, 162.5, 169.0. HRMS (ESI-MS): m/z calcd for C₃₃H₅₂N₃O₅S₂: 618.3394 [M+H]⁺; found 618.3386.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-10,13-Dimethyl-17-((*R*)-4-(5-((4-morpholino but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)hexadecahydro-1*H*-cyclopenta [a]phenanthrene-3,7,12-triol (4m)

Yellow oil (0.346 g, 96% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.65 (s, 3H, CH₃); 0.86 (m, 3H, CH₃); 1.02 (d, 3H, J= 6.1, CH₃); 1.35–1.91 (m, 20H, CH₂ and CH); 2.15-2.22 (m, 2H, CH₂); 2.53-2.57 (m, 4H, CH₂); 2.71-2.78 (m, 1H, CH); 2.80-2.94 (m, 1H, CH); 3.31 (s, 2H, CH₂); 3.38-3.43 (m, 1H, CH); 3.72-3.74 (m, 4H, CH₂); 3.82 (m, 1H, CH); 3.94 (m, 1H, CH); 4.00 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.4, 22.3, 22.4, 23.2, 26.3, 27.5, 28.1, 30.2, 32.3, 34.6, 34.7, 35.2, 35.3, 39.4, 39.5, 41.4, 41.6, 46.4, 46.5, 47.2, 51.9, 66.4, 68.4, 71.8, 72.9, 78.7, 79.5, 162.4, 169.1. HRMS (ESI-MS): m/z calcd for C₃₃H₅₂N₃O₅S: 602.3622 [M+H]⁺; found 602.3626.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(Benzyl(methyl)amino)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[a]phenanthrene-3,7,12-triol (4n)

Colorless oil (0.311 g, 82% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.63 (s, 3H, CH₃); 0.84 (s, 3H, CH₃); 1.00 (d, 3H, J= 5.2, CH₃); 1.30–1.95 (m, 20H, CH₂ and CH); 2.10-2.22 (m, 2H, CH₂); 2.22-2.30 (m, 3H, NCH₃); 2.72 (m, 1H, CH); 2.85 (m, 1H, CH); 3.19-3.40 (m, 3H, CH₂ and CH); 3.40-3.54 (s, 2H, CH₂); 3.70-3.87 (m, 1H, CH); 3.87-3.96 (m, 1H, CH); 4.02 (s, 2H, CH₂); 7.06-7.63 (m, 5H, CH-aromatic). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.6, 22.3, 22.4, 23.2, 26.3, 27.5, 28.2, 30.4, 32.3, 34.7, 35.2, 35.3, 39.4, 39.6, 41.4, 41.6, 44.9, 46.4, 46.6, 47.2, 51.7, 59.8, 68.4, 71.8, 72.9, 127.4, 128.4, 129.3, 141.2, 162.6, 169.2. HRMS (ESI-MS): m/z calcd for C₃₇H₅₄N₃O₄S: 636.3830 [M+H]⁺; found 636.3894.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-10,13-Dimethyl-17-((*R*)-4-(5-((4-(piperidin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4o)

Yellow oil (0.338 g, 94% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.65 (s, 3H, CH₃); 0.86 (m, 3H, CH₃); 1.02 (d, 3H, J = 6.0, CH₃); 1.31–1.80 (m, 20H, CH₂ and CH); 1.80–1.89 (m, 4H, CH₂); 2.00–2.05 (m, 2H, CH₂); 2.12–2.28 (m, 2H, CH₂); 2.47–2.66 (m, 6H, CH₂ and CH); 2.70–2.78 (m, 1H, CH); 2.81–2.95 (m, 1H, CH); 3.28–3.52 (m, 3H, CH₂ and CH); 3.82–3.94 (m, 4H, CH₂ and CH); 4.00 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.5, 22.3, 22.4, 23.2, 23.2, 25.0, 26.3, 27.5, 28.1, 30.3, 32.3, 34.6, 34.7, 35.2, 35.3, 39.4, 39.5, 41.4, 41.6, 46.4, 46.6, 47.2, 52.6, 68.4, 71.8, 72.9, 78.8, 79.5, 162.5, 169.1. HRMS (ESI-MS): m/z calcd for C₃₄H₅₄N₃O₅S: 600.3830 [M+H]⁺; found 600.3851.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-10,13-Dimethyl-17-((*R*)-4-(5-((4-(pyrrolidin-1-yl)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)hexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4p)

Yellow oil (0.331 g, 95% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.65 (s, 3H, CH₃); 0.86 (m, 3H, CH₃); 1.02 (d, 3H, J = 5.9, CH₃); 1.35–1.98 (m, 24H, CH₂ and CH); 2.11–2.33 (m, 2H, CH₂); 2.65–2.97 (m, 6H, CH₂ and CH); 3.31–3.47 (m, 1H, CH); 3.51 (s, 2H, CH₂); 3.75–3.87 (m, 1H, CH); 3.87–3.94 (m, 1H, CH); 3.99 (s, 2H, CH₂); 4.61 (br, 3H, OH). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 21.4, 22.3, 22.4, 23.2, 23.8, 26.3, 27.5, 28.1, 30.3, 32.4, 34.6, 34.7, 35.3, 35.3, 39.4, 39.5, 41.4, 41.6, 42.4, 46.4, 46.6, 51.6, 68.3, 71.8, 72.9, 78.3, 79.6, 162.4, 169.1. HRMS (ESI-MS): m/z calcd for C₃₃H₅₂N₃O₄S: 586.3673 [M+H]⁺; found 586.3670.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(Diisopropylamino)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4q)

Yellow oil (0.350 g, 95% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.62 (s, 3H, CH₃); 0.83 (s, 3H, CH₃); 0.99 (d, 3H, J = 6.4, CH₃); 1.10 (d, 12H, J = 6.4, CH₃); 1.30–1.92 (m, 20H, CH₂ and CH); 2.08–2.22 (m, 2H, CH₂); 2.63–2.74 (m, 1H, CH); 2.74–2.89 (m, 1H, CH); 3.24 (sep, 2H, CH); 3.30–3.41 (m, 1H, CH); 3.50 (s, 2H, CH₂); 3.79 (m, 1H, CH); 3.91 (m, 1H,

CH); 3.94 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 17.2, 19.8, 21.7, 22.3, 22.4, 23.2, 26.3, 27.5, 28.1, 30.3, 32.4, 34.2, 34.6, 34.7, 35.2, 35.3, 39.4, 39.5, 41.4, 41.6, 46.4, 46.6, 49.4, 68.4, 71.8, 72.9, 162.5, 169.0. HRMS (ESI-MS): m/z calcd for C₃₅H₅₈N₃O₄S: 616.4142 [M+H]⁺; found 616.4146.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(Diethylamino)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4r)

Yellow oil (0.288 g, 82% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.66 (s, 3H, CH₃); 0.87 (m, 3H, CH₃); 1.02-1.14 (m, 9H, CH₃); 1.30–1.98 (m, 20H, CH₂ and CH); 2.07-2.29 (m, 2H, CH₂); 2.47-2.56 (q, 4H, CH₂); 2.69-2.78 (m, 1H, CH); 2.81-2.91 (m, 1H, CH); 3.35-3.54 (m, 3H, CH₂ and CH); 3.82 (m, 1H, CH); 3.94 (m, 1H, CH); 3.99 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 12.2, 12.4, 17.2, 21.6, 22.3, 22.4, 23.2, 26.3, 27.5, 28.1, 30.3, 32.4, 34.7, 34.7, 35.2, 35.3, 39.4, 39.5, 40.7, 41.4, 41.6, 46.4, 46.6, 47.2, 68.4, 71.8, 72.9, 78.6, 79.1, 162.5, 169.0. HRMS (ESI-MS): m/z calcd for C₃₃H₅₄N₃O₄S: 588.3830 [M+H]⁺; found 588.3854.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(Dipropylamino)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4s)

Yellow oil (0.337 g, 91% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.68 (s, 3H, CH₃); 0.84-.93 (m, 9H, CH₃); 1.06 (d, 3H, J = 6.4, CH₃); 1.39–1.94 (m, 24H, CH₂ and CH); 2.14-2.26 (m, 2H, CH₂); 2.33-2.51 (m, 4H, CH₂); 2.70–2.80 (m, 1H, CH); 2.83–2.96 (m, 1H, CH); 3.37-3.47 (m, 3H, CH₂ and CH); 3.85 (m, 1H, CH); 3.97 (m, 1H, CH); 4.03 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 11.8, 12.4, 17.2, 20.4, 21.6, 22.3, 22.4, 23.2, 26.3, 27.5, 28.2, 30.4, 32.4, 34.7, 34.7, 35.2, 35.3, 39.4, 39.5, 41.4, 41.6, 42.1, 46.4, 46.6, 55.6, 68.4, 71.8, 72.9, 78.4, 79.7, 162.6, 169.0. HRMS (ESI-MS): m/z calcd for C₃₅H₅₈N₃O₄S: 616.4143 [M+H]⁺; found 616.4119.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(Dibutylamino)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4t)

Yellow oil (0.366 g, 95% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.67 (s, 3H, CH₃); 0.84–0.93 (m, 9H, CH₃); 1.04 (d, 3H, J = 6.4, CH₃); 1.22–1.89 (m, 28H, CH₂ and CH); 2.14–2.26 (m, 2H, CH₂); 2.39–2.52 (m, 4H, CH₂); 2.79–2.85 (m, 1H, CH); 2.85–2.90 (m, 1H, CH); 3.38–3.50 (m, 3H, CH₂ and CH); 3.84 (m, 1H, CH); 3.96 (m, 1H, CH); 4.01 (s, 2H, CH₂). ¹³C NMR (125 MHz, CDCl₃): δ 12.5, 14.0, 17.3, 20.6, 21.6, 22.3, 22.4, 23.2, 26.4, 27.5, 28.2, 29.2, 30.4, 32.4, 34.6, 34.7, 35.2, 35.2, 39.5, 39.6, 41.4, 41.7, 42.0, 46.4, 46.7, 53.4, 68.4, 71.9, 72.9, 162.6, 168.9. HRMS (ESI-MS): m/z calcd for C₃₇H₆₂N₃O₄S: 644.4456 [M+H]⁺; found 644.4476.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(Dihexylamino)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4u)

Yellow oil (0.365 g, 88% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.66 (s, 3H, CH₃); 0.79–0.92 (m, 9H, CH₃); 1.02 (m, 3H, CH₃); 1.17–1.95 (m, 36H, CH₂ and CH); 2.13–2.21 (m, 2H, CH₂); 2.43–2.55 (m, 4H, CH₂); 2.67–2.76 (m, 1H, CH); 2.81–2.89 (m, 1H, CH); 3.32–3.58 (m, 3H, CH₂ and CH); 3.82 (m, 1H, CH); 3.94 (m, 1H, CH); 4.01 (s, 2H, CH₂); 4.07–4.02 (bs, 3H, OH). ¹³C NMR (125 MHz, CDCl₃): δ 12.4, 14.0, 17.2, 21.5, 22.3, 22.4, 22.5, 23.2, 26.3, 26.5, 27.0, 27.5, 28.1, 30.3, 31.6, 32.4, 34.6, 34.7, 35.2, 35.2, 39.4, 39.5, 41.4, 41.6, 41.7, 46.4, 46.6, 53.5, 68.4, 71.8, 73.0, 78.5, 79.2, 162.5, 169.0. HRMS (ESI-MS): m/z calcd for C₄₁H₇₀N₃O₄S: 700.5082 [M+H]⁺; found 700.5097.

(3*R*,5*S*,7*R*,8*R*,9*S*,10*S*,12*S*,13*R*,14*S*,17*R*)-17-((*R*)-4-(5-((4-(Dicyclohexylamino)but-2-yn-1-yl)thio)-1,3,4-oxadiazol-2-yl)butan-2-yl)-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthrene-3,7,12-triol (4v)

Brown oil (0.382 g, 92% yield). ¹H NMR (500 MHz, CDCl₃): δ 0.64 (s, 3H, CH₃); 0.85 (s, 3H, CH₃); 1.01 (d, 3H, J = 6.4, CH₃); 1.15–1.94 (m, 40H, CH₂ and CH); 2.06–2.27 (m, 2H, CH₂); 2.72–2.77 (m, 2H, CH); 2.82–2.86 (m, 2H, CH); 3.31–3.43 (m, 1H, CH); 3.50 (s, 2H, CH₂); 3.80 (m, 1H, CH); 3.92 (m, 1H, CH); 3.96 (s, 2H, CH₂). ¹³C NMR (125

MHz, CDCl₃): δ 12.4, 17.2, 21.7, 22.2, 22.3, 23.1, 25.9, 25.9, 26.2, 27.4, 28.0, 30.2, 30.6, 32.3, 34.6, 34.7, 35.1, 35.2, 35.3, 39.4, 39.5, 41.4, 41.5, 46.3, 46.5, 57.7, 68.3, 71.7, 72.9, 162.6, 168.9. HRMS (ESI-MS): m/z calcd for C₄₁H₆₆N₃O₄S: 696.4769 [M+H]⁺; found 696.4781.

2. Antimicrobial activity assay

The antimicrobial activity of the newly synthesized compounds was investigated in order to determine the activity of these derivatives towards test microorganisms. All microbial strains were provided from culture collection of the Regional Center for Mycology and Biotechnology (RCMB), Al-Azhar University, Cairo, Egypt.


In a similar manner to a procedure from [1], the antimicrobial profile was tested against Gram-positive bacterial species (*Staphylococcus aureus* and *Bacillus subtilis*), Gram-negative bacterial species (*Escherichia coli*, *Proteus vulgaris*), as well as against fungi including one filamentous fungus (*Aspergillus fumigatus*) and one yeast species (*Candida albicans*) using a well diffusion method [2]. Briefly, 100 μ L of the test bacteria/fungi were grown in 10 mL of fresh media until they reached a count of approximately 10^8 cells/mL for bacteria or 10^5 cells/mL for fungi. One hundred μ L of the microbial suspension was spread onto agar plates corresponding to the broth in which they were maintained and tested for susceptibility by the well diffusion method. One hundred μ L of each sample (at 10 mg/mL) was added to each well (6 mm diameter holes cut in the agar gel). The plates were incubated for 24 h at 37 °C (for bacteria and yeast) and for 48 h at 28 °C (for filamentous fungi). After incubation, the microorganisms' growth was evaluated. The resulting inhibition zone diameters were measured in millimeters and used as the criterion for the antimicrobial activity. If an organism was placed on the agar it would have not grown in the area around the well if it was susceptible to the chemical. This area of no growth around the well is known as a zone of inhibition and the size of this zone is proportional to the inhibitory action of the compound under investigation. Solvent controls (DMSO) were included in every experiment as negative control and showed no inhibition zones, confirming that it had no influence on growth of the tested microorganisms.


Positive controls were also performed using gentamycin as broad spectrum standard antibacterial drugs and ketoconazole as broad spectrum standard antifungal drug. For all biologically active samples MIC values were determined by the broth microdilution method. Briefly, the microbes were grown on Mueller Hinton broth media on sterile microtiter plates and inoculated with the tested microorganism. Then, the plates were

treated with the tested compound (at 10 mg/mL) followed by a serial two-fold dilution to test a range of concentrations from 10000 to 1 µg/mL). After the end of incubation, the lowest concentration showing complete inhibition of growth was recorded as the MIC of the respective sample [2]. The results reported are means of at least three separate experiments each with three replicates.



3. NMR spectra


Compound 2





Compound 3






Chemical structure of compound 10 is shown above the ^1H NMR spectrum. The spectrum displays peaks corresponding to the structure, with chemical shifts (ppm) and integration values indicated.



Chemical shifts (ppm): 7.24, 7.18, 6.98, 6.89, 6.85, 6.78, 3.99, 3.91, 3.80, 3.38, 3.21, 2.84, 2.71, 2.29, 2.28, 2.27, 2.26, 2.25, 2.24, 2.23, 2.22, 2.21, 2.20, 2.19, 2.18, 2.17, 2.16, 2.15, 2.14, 2.13, 2.12, 2.11, 2.10, 2.09, 2.08, 2.07, 2.06, 2.05, 2.04, 2.03, 2.02, 2.01, 2.00, 1.99, 1.98, 1.97, 1.96, 1.95, 1.94, 1.93, 1.92, 1.91, 1.90, 1.89, 1.88, 1.87, 1.86, 1.85, 1.84, 1.83, 1.82, 1.81, 1.80, 1.79, 1.78, 1.77, 1.76, 1.75, 1.74, 1.73, 1.72, 1.71, 1.70, 1.69, 1.68, 1.67, 1.66, 1.65, 1.64, 1.63, 1.62, 1.61, 1.60, 1.59, 1.58, 1.57, 1.56, 1.55, 1.54, 1.53, 1.52, 1.51, 1.50, 1.49, 1.48, 1.47, 1.46, 1.45, 1.44, 1.43, 1.42, 1.41, 1.40, 1.39, 1.38, 1.37, 1.36, 1.35, 1.34, 1.33, 1.32, 1.31, 1.30, 1.29, 1.28, 1.27, 1.26, 1.25, 1.24, 1.23, 1.22, 1.21, 1.20, 1.19, 1.18, 1.17, 1.16, 1.15, 1.14, 1.13, 1.12, 1.11, 1.10, 1.09, 1.08, 1.07, 1.06, 1.05, 1.04, 1.03, 1.02, 1.01, 1.00, 0.99, 0.98, 0.97, 0.96, 0.95, 0.94, 0.93, 0.92, 0.91, 0.90, 0.89, 0.88, 0.87, 0.86, 0.85, 0.84, 0.83, 0.82, 0.81, 0.80, 0.79, 0.78, 0.77, 0.76, 0.75, 0.74, 0.73, 0.72, 0.71, 0.70, 0.69, 0.68, 0.67, 0.66, 0.65, 0.64, 0.63, 0.62, 0.61, 0.60, 0.59, 0.58, 0.57, 0.56, 0.55, 0.54, 0.53, 0.52, 0.51, 0.50, 0.49, 0.48, 0.47, 0.46, 0.45, 0.44, 0.43, 0.42, 0.41, 0.40, 0.39, 0.38, 0.37, 0.36, 0.35, 0.34, 0.33, 0.32, 0.31, 0.30, 0.29, 0.28, 0.27, 0.26, 0.25, 0.24, 0.23, 0.22, 0.21, 0.20, 0.19, 0.18, 0.17, 0.16, 0.15, 0.14, 0.13, 0.12, 0.11, 0.10, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.00.


Integration values: 2.13, 2.18, 0.77, 2.27, 1.14, 1.14, 3.50, 4.39, 2.15, 4.41, 2.48, 20.08, 2.92, 3.47, 3.00.





Compound 4b






Chemical structure of compound 10 is shown above the spectrum. The structure is a steroid derivative with a 17-ethynyl-1H-tetrazol-5-yl side chain.

¹H NMR spectrum (CDCl₃) of compound 10. The x-axis represents chemical shift in ppm, ranging from 0.0 to 10.0. The spectrum shows several peaks, with integration values provided below the baseline and chemical shifts listed on the right side of the spectrum.



Integration values (from left to right): 4.50, 3.00, 2.36, 1.21, 1.18, 3.01, 4.13, 6.10, 2.09, 20.07, 3.16, 3.29, 3.21.


Chemical shifts (ppm) listed on the right side of the spectrum (from top to bottom): 7.16, 6.90, 5.99, 4.48, 4.25, 4.04, 3.95, 3.83, 3.54, 3.37, 3.28, 3.09, 3.01, 2.64, 2.24, 2.18, 1.98, 1.31, 1.02, 1.01, 0.87, 0.66.






Compound 4d





Chemical structure of compound 10 is shown above the ^1H NMR spectrum. The ^1H NMR spectrum (top) shows peaks from 0.0 to 10.0 ppm with integrations. The ^{13}C NMR spectrum (bottom) shows peaks from 12.4 to 51.7 ppm. The solvent DMSO is indicated at 2.5 ppm in the ^1H NMR spectrum.






Chemical structure of compound 10 is shown above the spectrum. The structure is a steroid derivative with a side chain containing a 1,2,4-triazole ring, a thioether linkage, an alkyne, a piperazine ring, and a 4-acetylphenyl group.

¹H NMR spectrum (DMSO-d₆) showing peaks from 0.0 to 10.0 ppm. Key peaks include:

- Aromatic protons: ~7.2 ppm (2H, s)
- Acetyl methyl: ~2.6 ppm (3H, s)
- Piperazine protons: ~3.5 ppm (4H, m)
- Alkyne protons: ~2.3 ppm (2H, s)
- Thioether protons: ~2.1 ppm (2H, m)
- Triazole protons: ~7.8 ppm (2H, s)
- Steroid protons: 0.5 - 5.0 ppm

Integration values are provided below the baseline, and chemical shifts are listed at the top.






Chemical structure of compound 10 is shown above the ^1H NMR spectrum. The spectrum is recorded in EtOAc and displays peaks corresponding to the structure, with integration values indicated below the baseline.

Chemical shift range (ppm): 10.0 to 0.0.



Integration values (from left to right): 2.10, 1.12, 1.09, 2.00, 1.35, 2.27, 1.42, 1.48, 10.44, 2.31, 19.71, 3.25, 3.00.


Peak labels (from left to right): EtOAc , EtOAc , EtOAc .








Compound 4h








Compound 4i








Compound 4j





Compound 4k






Chemical structure of compound **1** is shown above the ^1H NMR spectrum. The structure is a complex steroid derivative with a side chain containing a 1,3,4-oxadiazole ring, a thioether linkage, an alkyne, and a morpholine ring.


The ^1H NMR spectrum (DMSO- d_6) shows peaks from 0.0 to 10.0 ppm. Key peaks are labeled with their chemical shifts and integrations:

- 7.95 (s, 1H, integration 1.04)
- 7.29 (s, 1H, integration 1.04)
- 6.83 (s, 1H, integration 1.04)
- 4.27 (s, 2H, integration 2.44)
- 4.39 (s, 2H, integration 2.44)
- 2.50 (s, 3H, integration 3.00)
- 2.44 (s, 3H, integration 3.00)
- 2.32 (s, 3H, integration 3.00)
- 2.24 (s, 3H, integration 3.00)
- 2.15 (s, 3H, integration 3.00)
- 2.08 (s, 3H, integration 3.00)
- 1.92 (s, 3H, integration 3.00)
- 1.84 (s, 3H, integration 3.00)
- 1.76 (s, 3H, integration 3.00)
- 1.68 (s, 3H, integration 3.00)
- 1.60 (s, 3H, integration 3.00)
- 1.52 (s, 3H, integration 3.00)
- 1.44 (s, 3H, integration 3.00)
- 1.36 (s, 3H, integration 3.00)
- 1.28 (s, 3H, integration 3.00)
- 1.20 (s, 3H, integration 3.00)
- 1.12 (s, 3H, integration 3.00)
- 1.04 (s, 3H, integration 3.00)
- 0.96 (s, 3H, integration 3.00)
- 0.88 (s, 3H, integration 3.00)
- 0.80 (s, 3H, integration 3.00)
- 0.72 (s, 3H, integration 3.00)
- 0.64 (s, 3H, integration 3.00)
- 0.56 (s, 3H, integration 3.00)
- 0.48 (s, 3H, integration 3.00)
- 0.40 (s, 3H, integration 3.00)
- 0.32 (s, 3H, integration 3.00)
- 0.24 (s, 3H, integration 3.00)
- 0.16 (s, 3H, integration 3.00)
- 0.08 (s, 3H, integration 3.00)
- 0.00 (s, 3H, integration 3.00)






[illegible]





Chemical structure of compound **1** is shown above the ¹H NMR spectrum. The structure is a steroid derivative with a complex side chain at C-17. The side chain includes a 1,3,4-oxadiazole ring, a thioether linkage, an alkyne, and a 1-methyl-2-phenylethan-1-amine moiety.


The ¹H NMR spectrum (CDCl₃) shows peaks from 0.5 to 10.0 ppm. Key peaks include a broad singlet for the hydroxyl group at ~9.8 ppm, a sharp singlet for the methyl group at C-13 at ~7.2 ppm, and a complex set of peaks in the aliphatic region between 1.0 and 4.0 ppm. Integration values are provided below the baseline.









Compound 4o








Compound 4p











Compound 4q








Compound 4r








Compound 4s








Compound 4t





Compound 4u





Chemical structure of compound **1** is shown above the ^1H NMR spectrum. The structure is a steroid derivative with a side chain containing a 1,2,4-triazole ring, a thioether linkage, an alkyne, and a diphenylmethyl group.

The ^1H NMR spectrum (DMSO- d_6) shows peaks from 0.5 to 9.5 ppm. Integration values are provided below the baseline, and chemical shifts are listed on the right.

Integration values (from left to right): 2.01, 1.02, 1.10, 1.96, 1.31, 2.35, 1.96, 2.36, 39.77, 3.14, 3.22, 3.00.

Chemical shifts (ppm) listed on the right (from top to bottom): 3.96, 3.92, 3.80, 3.54, 3.46, 3.35, 3.31, 2.86, 2.82, 2.77, 2.72, 2.27, 2.06, 1.94, 1.15, 1.01, 0.85, 0.64.





4. References

1. Abbas, I.; Gomha, S.; Elneairy, M.; Elaasser, M.; Mabrouk, B. *Turkish Journal of Chemistry* **2015**, 39, 510-531.
2. Abo-Ashour, M. F.; Eldehna, W. M.; George, R. F.; Abdel-Aziz, M. M.; Elaasser, M. M.; Gawad, N. M. A.; Gupta, A.; Bhakta, S.; Abou-Seri, S. M. *Eur. J. Med. Chem.* **2018**, 160, 49-60.